azathioprine has been researched along with Fibrosis in 22 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the degree of interstitial fibrosis in renal transplant biopsy specimens from immunosuppressed patients using conventional doses of cyclosporin with and without calcium channel blockade with a combination of low dose cyclosporin and azathioprine; to correlate the degree of interstitial fibrosis with the glomerular filtration rate." | 9.07 | Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. ( Bell, PR; Donnelly, PK; Feehally, J; Furness, PN; Harper, SJ; McCulloch, TA; Moorhouse, J; Walls, J, 1994) |
| "To compare the degree of interstitial fibrosis in renal transplant biopsy specimens from immunosuppressed patients using conventional doses of cyclosporin with and without calcium channel blockade with a combination of low dose cyclosporin and azathioprine; to correlate the degree of interstitial fibrosis with the glomerular filtration rate." | 5.07 | Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. ( Bell, PR; Donnelly, PK; Feehally, J; Furness, PN; Harper, SJ; McCulloch, TA; Moorhouse, J; Walls, J, 1994) |
| "The effect of mycophenolate mofetil (MMF) and azathioprine (AZA) in reducing renal interstitial fibrosis in rats with unilateral ureteral obstruction (UUO) was studied." | 3.72 | Comparison of mycophenolate mofetil and azathioprine in obstructive nephropathy. ( Anarat, A; Bayazit, AK; Bayazit, Y; Gonlusen, G; Noyan, A, 2003) |
| "Chronic cyclosporine nephrotoxicity is characterized morphologically by cortical interstitial fibrosis." | 3.69 | Serum propeptides of type I and III procollagens in renal transplant recipients. A comparison of cyclosporine and azathioprine treatment. ( Frost, L; Heickendorff, L; Madsen, JK; Pedersen, EB, 1994) |
| "Tacrolimus treatment was safe and well tolerated." | 2.71 | Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. ( Aqel, BA; Dickson, RC; Harnois, DM; Machicao, V; Rosser, B; Satyanarayana, R, 2004) |
| "Lupus panniculitis is a rare variant of cutaneous lupus erythematosus." | 1.29 | [Kaposi-Irgang lupus erythematosus profundus. Lupus erythematosus panniculitis]. ( Lübke, S; Meurer, M; Ruzicka, T; Schirren, CG; Süss, R, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 7 (31.82) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, AW | 1 |
| Khor, YH | 1 |
| Donohoe, K | 1 |
| Comes, A | 1 |
| Marcoux, V | 1 |
| Fisher, JH | 1 |
| Johannson, KA | 1 |
| Assayag, D | 1 |
| Morisset, J | 1 |
| Shapera, S | 1 |
| Khalil, N | 1 |
| Fell, CD | 1 |
| Manganas, H | 1 |
| Cox, G | 1 |
| To, T | 1 |
| Gershon, AS | 1 |
| Hambly, N | 1 |
| Halayko, AJ | 1 |
| Sadatsafavi, M | 1 |
| Wilcox, PG | 1 |
| Kolb, M | 1 |
| Richeldi, L | 1 |
| Ryerson, CJ | 1 |
| Kiboshi, T | 1 |
| Kotani, T | 1 |
| Konma, J | 1 |
| Makino, H | 1 |
| Matsuda, S | 1 |
| Suzuka, T | 1 |
| Wada, Y | 1 |
| Shiba, H | 1 |
| Hata, K | 1 |
| Shoda, T | 1 |
| Takeuchi, T | 1 |
| Aljumah, AA | 1 |
| Al Jarallah, B | 1 |
| Albenmousa, A | 1 |
| Al Khathlan, A | 1 |
| Al Zanbagi, A | 1 |
| Al Quaiz, M | 1 |
| Al-Judaibi, B | 1 |
| Nabrawi, K | 1 |
| Al Hamoudi, W | 1 |
| Alghamdi, M | 1 |
| Fallatah, H | 1 |
| Stangou, M | 1 |
| Papagianni, A | 1 |
| Bantis, C | 1 |
| Moisiadis, D | 1 |
| Kasimatis, S | 1 |
| Spartalis, M | 1 |
| Pantzaki, A | 1 |
| Efstratiadis, G | 1 |
| Memmos, D | 1 |
| Quillinan, NP | 1 |
| Denton, CP | 1 |
| Dell'Oglio, MP | 1 |
| Zaza, G | 1 |
| Rossini, M | 1 |
| Divella, C | 1 |
| Pontrelli, P | 1 |
| Verrienti, R | 1 |
| Rutigliano, M | 1 |
| Ditonno, P | 1 |
| Stifanelli, P | 1 |
| Ancona, N | 1 |
| Schena, FP | 1 |
| Grandaliano, G | 1 |
| Bang, S | 1 |
| Park, JY | 1 |
| Bayazit, AK | 1 |
| Bayazit, Y | 1 |
| Noyan, A | 1 |
| Gonlusen, G | 1 |
| Anarat, A | 1 |
| Kyhn, M | 1 |
| Herning, M | 1 |
| Prause, JU | 1 |
| Heegaard, S | 1 |
| Aqel, BA | 1 |
| Machicao, V | 1 |
| Rosser, B | 1 |
| Satyanarayana, R | 1 |
| Harnois, DM | 1 |
| Dickson, RC | 1 |
| Päiväniemi, OE | 1 |
| Maasilta, PK | 1 |
| Alho, HS | 1 |
| Wolff, CH | 1 |
| Salminen, US | 2 |
| Kornberg, A | 1 |
| Küpper, B | 1 |
| Tannapfel, A | 1 |
| Hommann, M | 1 |
| Scheele, J | 1 |
| Laine, J | 1 |
| Krogerus, L | 1 |
| Jalanko, H | 1 |
| Rönnholm, K | 1 |
| Holmberg, C | 1 |
| McCulloch, TA | 1 |
| Harper, SJ | 1 |
| Donnelly, PK | 1 |
| Moorhouse, J | 1 |
| Bell, PR | 1 |
| Walls, J | 1 |
| Feehally, J | 1 |
| Furness, PN | 1 |
| Budihna, NV | 1 |
| Milcinski, M | 1 |
| Kajtna-Koselj, M | 1 |
| Malovrh, M | 1 |
| Heickendorff, L | 1 |
| Frost, L | 1 |
| Madsen, JK | 1 |
| Pedersen, EB | 1 |
| Süss, R | 1 |
| Meurer, M | 1 |
| Schirren, CG | 1 |
| Lübke, S | 1 |
| Ruzicka, T | 1 |
| Uusitalo, M | 1 |
| Ikonen, T | 1 |
| Taskinen, E | 1 |
| Morris, RE | 1 |
| Harjula, AL | 1 |
| Streichenberger, N | 1 |
| Peyrol, S | 1 |
| Philit, F | 1 |
| Loire, R | 1 |
| Sommer, P | 1 |
| Cordier, JF | 1 |
| Schoeman, MN | 1 |
| Liddle, C | 1 |
| Bilous, M | 1 |
| Grierson, J | 1 |
| Craig, PI | 1 |
| Batey, RG | 1 |
| Farrell, GC | 1 |
| Alfani, D | 1 |
| Berloco, P | 1 |
| Renna Molajoni, E | 1 |
| Pretagostini, R | 1 |
| Famulari, A | 1 |
| Sallustio, F | 1 |
| Caricato, M | 1 |
| Rossi, M | 1 |
| Pecorella, I | 1 |
| Ciardi, A | 1 |
| Klintmalm, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection[NCT01134952] | Phase 4 | 11 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 9 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 13.8 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -6.0 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 1.2 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -2.7 |
Percent change in HCV load determined 3 months after switch from MMF to SRL. (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 15 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -8.5 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 23 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 23 |
Percent change in HCV load determined 3 months after switch from SRL to MMF (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -47 |
(NCT01134952)
Timeframe: 3 month
| Intervention | ng/ml (Mean) |
|---|---|
| MMF SRL Switch | 7.2 |
1 review available for azathioprine and Fibrosis
| Article | Year |
|---|---|
Disease-modifying treatment in systemic sclerosis: current status.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantigens; Azathioprine; Collagen | 2009 |
3 trials available for azathioprine and Fibrosis
| Article | Year |
|---|---|
Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis.
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Biopsy; Female; Fibrosis; Follow-Up Studies; Hepatitis | 2004 |
Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation.
Topics: Adult; Azathioprine; Cyclosporine; Female; Fibrosis; Graft Rejection; Hepatitis C; Humans; Immunosup | 2005 |
Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A.
Topics: Azathioprine; Cyclosporine; Fibrosis; Glomerular Filtration Rate; Humans; Immunosuppression Therapy; | 1994 |
18 other studies available for azathioprine and Fibrosis
| Article | Year |
|---|---|
Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease.
Topics: Azathioprine; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Lung Diseas | 2022 |
Comparison of therapeutic effects of combination therapy with prednisolone and tacrolimus or azathioprine on progressive interstitial pneumonia with systemic sclerosis.
Topics: Azathioprine; Drug Therapy, Combination; Fibrosis; Humans; Immunosuppressive Agents; Lung Diseases, | 2022 |
The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis.
Topics: Adult; Azathioprine; Female; Fibrosis; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Live | 2018 |
Up-regulation of urinary markers predict outcome in IgA nephropathy but their predictive value is influenced by treatment with steroids and azathioprine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Azathioprine; Biomarkers; Biopsy; Creatinine; Cytokin | 2013 |
The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase.
Topics: Administration, Oral; Adult; Aged; Azathioprine; Cyclosporine; Dose-Response Relationship, Drug; Dru | 2010 |
[Suspected pulmonary involvement of autoimmune pancreatitis].
Topics: Autoimmune Diseases; Azathioprine; Common Bile Duct; Emphysema; Fibrosis; Humans; Immunoglobulin G; | 2011 |
Comparison of mycophenolate mofetil and azathioprine in obstructive nephropathy.
Topics: Animals; Azathioprine; Collagen; Fibronectins; Fibrosis; Immunohistochemistry; Kidney Diseases; Myco | 2003 |
Orbital involvement in multifocal fibrosclerosis.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Fibrosis; Glucocorticoids; Humans; Immunosup | 2004 |
Cyclooxygenase-2 expression in experimental post-transplant obliterative bronchiolitis.
Topics: Animals; Azathioprine; Bronchi; Bronchiolitis Obliterans; Chondrocytes; Cyclooxygenase 2; Cyclospori | 2004 |
Renal allograft histology and correlation with function in children on triple therapy.
Topics: Adolescent; Atrophy; Azathioprine; Child; Child, Preschool; Cyclosporine; Drug Therapy, Combination; | 1995 |
Relevance of Tc-99m DMSA scintigraphy in renal transplant parenchymal imaging.
Topics: Acute Disease; Adult; Azathioprine; Creatinine; Cyclosporine; Edema; Female; Fibrosis; Glucocorticoi | 1994 |
Serum propeptides of type I and III procollagens in renal transplant recipients. A comparison of cyclosporine and azathioprine treatment.
Topics: Adolescent; Adult; Aged; Azathioprine; Collagen; Creatinine; Cyclosporine; Female; Fibrosis; Humans; | 1994 |
[Kaposi-Irgang lupus erythematosus profundus. Lupus erythematosus panniculitis].
Topics: Adipose Tissue; Azathioprine; Basement Membrane; Complement C3; Connective Tissue; Drug Therapy, Com | 1994 |
Effect of immunosuppression on obliterative lesions in a heterotopic large-animal bronchial allograft model.
Topics: Animals; Azathioprine; Bronchi; Bronchiolitis Obliterans; Cartilage; Cyclosporine; Drug Therapy, Com | 1997 |
Constrictive bronchiolitis obliterans. Characterisation of fibrogenesis and lysyl oxidase expression patterns.
Topics: Adult; Azathioprine; Biomarkers; Bone Marrow Transplantation; Bronchiolitis Obliterans; Drug Therapy | 2001 |
Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity, and effects of immunosuppressive therapy on disease progression.
Topics: Adult; Aged; Azathioprine; Biopsy; Female; Fibrosis; Follow-Up Studies; Hepatitis C; Hepatitis, Vira | 1990 |
The effect of cyclosporine on long-term function in patients undergoing kidney transplant from living donors.
Topics: Azathioprine; Cyclosporins; Fibrosis; Follow-Up Studies; Humans; Kidney Transplantation; Methylpredn | 1987 |
Development of chronic renal cyclosporin-A toxicity.
Topics: Azathioprine; Biopsy; Cyclosporins; Drug Administration Schedule; Fibrosis; Humans; Kidney; Kidney T | 1987 |